The overall objective of this proposal is to examine the feasibility of targeting disseminated metastatic cancer using intact antibody and antibody fragments radiolabeled with the alpha-particle emitter Bi-213 (T1/2= 45.6 min). We propose to test the following hypotheses: 1. Due to the permeable vasculature of early tumor metastases, the 45.6 minute half-life of Bi-213 is sufficiently long to target both vascularized and pre- vascularized early cancer metastases. 2. The 45.6 minute half-life of Bi-213 relaxes the constraint that the antibody exhibit no cross-reactivity with normal organs because penetration of the antibody into intact normal organs will occur after the radionuclide has decayed and also because the short 4-5 cell diameter range of alpha-particles will irradiate targeted tumor cells with minimal adjacent normal cell irradiation. The hypotheses will be tested using Neu-N transgenic mice bearing lung, liver and osteolytic bone metastases.
SPECIFIC AIMS 1. Determine the relative expression of the rat/neu (analog to HER2/neu) receptor in tumors and in selected normal organs of the transgenic Neu-N murine model of breast carcinoma. 2. Determine the kinetics, in vivo, and spatial distribution, ex vivo, in tumors and normal organs of anti-neu IgG, F(ab')2, and Fab. 3. Evaluate the MTD and determine the dose-limiting organ in Neu-N mice treated with 213Bi-labeled anti-neu constructs. 4. Evaluate the efficacy of 213Bi-labeled anti-neu constructs against sub-cutaneous tumor and against lung, liver and bone metastases. 5. Perform microdosimetry to derive dose-response relationships to understand observed responses and toxicity in terms of absorbed dose. Current cancer treatment is rarely effective once the tumor has metastasized to distant sites. The eradication of such metastases requires a systemic, targeted therapy that is minimally susceptible to chemo- or radio-resistance, that is potent enough to sterilize individual tumor cells and cell clusters and that exhibits an acceptable toxicity. The work described in this application is intended to develop and evaluate such an approach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA113797-03
Application #
7317817
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Wong, Rosemary S
Project Start
2005-12-09
Project End
2009-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
3
Fiscal Year
2008
Total Cost
$278,677
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
McDevitt, Michael R; Sgouros, George; Sofou, Stavroula (2018) Targeted and Nontargeted ?-Particle Therapies. Annu Rev Biomed Eng 20:73-93
Josefsson, Anders; Nedrow, Jessie R; Park, Sunju et al. (2016) Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res 76:472-9
Song, Hong; Hedayati, Mohammad; Hobbs, Robert F et al. (2013) Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 12:2043-54
Hobbs, Robert F; Baechler, Sébastien; Fu, De-Xue et al. (2011) A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys 38:2892-903
Lingappa, Mohanambe; Song, Hong; Thompson, Sarah et al. (2010) Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res 70:6815-23
Song, Hong; Hobbs, Robert F; Vajravelu, Ravy et al. (2009) Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 69:8941-8
Sgouros, George; Song, Hong (2008) Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. Cancer Biother Radiopharm 23:74-81
Song, Hong; Shahverdi, Karineh; Huso, David L et al. (2008) 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 68:3873-80
Song, Hong; Shahverdi, Karineh; Huso, David L et al. (2008) An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res 14:6116-24